LISATA THERAPEUTICS, INC. — Capital/Financing Update 2017

Sep 15, 2017

CORRESP 1 filename1.htm html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" Document created using Wdesk 1 Copyright 2017 Workiva Document

Caladrius Biosciences, Inc.

110 Allen Road, Second Floor

Basking Ridge, NJ 07920

September 15, 2017

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jonathan Burr, Assistant Director

RE: Caladrius Biosciences, Inc.

Registration Statement on Form S-3

File No. 333-220354

Acceleration Request

Dear Mr. Burr:

With respect to the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of Caladrius Biosciences, Inc. (the “Company”), that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the Registration Statement to Tuesday, September 19, 2017, at 9:30 a.m. Eastern Time, or as soon as practicable thereafter.

The cooperation of the staff in meeting the timetable described above is very much appreciated.

Please call Jeffrey P. Schultz of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (212) 692-6732 with any comments or questions regarding the Registration Statement.

Very truly yours,

Caladrius Biosciences, Inc.

/s/ David J. Mazzo_____

By: David J. Mazzo

Its: Chief Executive Officer

cc: Todd Girolamo, Caladrius Biosciences, Inc.

Jeffrey P. Schultz, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.